Genexine Inc. (KOSDAQ:A095700) and SCM Lifescience Co. entered into an asset purchase agreement to acquire substantially all of the assets of Argos Therapeutics Inc. for $11.3 million on January 22, 2019. The joint tender of Genexine and SCM Lifescience was declared as the winning bid for Argos. The transaction is subject to approval of Pharmstandard having consented to the sale of the acquired assets to the purchasers and approval of the Bankruptcy Court. The Bankruptcy Court approved the agreement on January 23, 2019. Argos will be renamed as CoImmune and operate as an independent entity in the U.S. George Shuster of Wilmer Cutler Pickering Hale and Dorr LLP and Adam G. Landis, Matthew B. McGuire and Matthew R. Pierce of Landis Rath & Cobb LLP acted as legal advisor to Argos. Stuart Komrower of Cole Schotz, P.C. acted as legal advisor to SCM Lifescience.

Genexine Inc. (KOSDAQ:A095700) and SCM Lifescience Co. completed the acquisition of substantially all of the assets of Argos Therapeutics Inc. on February 13, 2019.